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Introduction
The metabotropic glutamate receptor subtype 5 (mGluR51 ) is a target for drug development and for molecular imaging of the glutamate system in neurological and psychiatric disorders (Pillai and Tipre, 2016) . Modulation of mGluR5 activity has been suggested as a mechanism for the treatment of several conditions, such as pain, depression, anxiety and levodopainduced dyskinesia (Emmitte, 2013) . For such purposes, a number of non-competitive mGluR5 antagonists (negative allosteric modulators; NAMs) have been developed, of which the majority are structural analogues of the prototype mGluR5 NAM MPEP (Gasparini et al., 1999) . Fenobam, a compound developed by McNeil Laboratories (Porter et al., 2005) and AZD9272 developed by AstraZeneca  Fig. 1 ) are structurally distinct, non-alkyne-containing, mGluR5 NAMs having reached clinical research. However, both compounds were discontinued due to observations of psychotic symptoms in early clinical trials (Friedmann et al., 1980; Pecknold et al., 1982; Ståhle et al., 2012) . Interestingly, in contrast to fenobam and AZD9272, other mGluR5 NAM drug candidates have shown favorable safety profiles and reached more advanced stages of clinical evaluation (Quiroz et al., 2016) .
Imaging of brain mGluR5 can be achieved using positron emission tomography (PET) 1 Abbreviations: AIC, Akaike information criterion; BP ND , binding potential relative to non-displaceable binding; DVR, distribution volume ratio; FWHM, full width at half maximum; HEPES, 4-(2-hydroxyethyl)-1-employing mGluR5-selective radioligands. Of the mGluR5 PET radioligands hitherto developed, [ 11 C]ABP688 (Ametamey et al., 2007) and [ 18 F]FPEB (Sullivan et al., 2013; Wong et al., 2013) have been the most widely applied in human studies. The drug candidate mentioned above, AZD9272, has also been radiolabeled with carbon-11 and evaluated as a potential mGluR5 radioligand in non-human primates (NHPs) and human subjects Andersson et al., 2013; Varnäs et al., 2018) . Importantly, an unexpected observation during development of the radioligand [ 11 C]AZD9272 was that the regional binding pattern appeared to be different from that of [ 11 C]ABP688 and other mGluR5 radioligands. Moreover, while the binding of [ 11 C]AZD9272 in NHP brain could be inhibited by fenobam, the binding could only partly be displaced by MPEP-like mGluR5 NAMs (Varnäs et al., 2018) suggesting that fenobam and AZD9272 recognize additional, potentially non-mGluR5-related binding sites. Insight into the nature of this binding is of interest for understanding the pharmacology of fenobam and AZD9272 in humans and to identify a potential pro-psychotic mechanism.
In line with the above, visual inspection of PET parametric images ( Fig. 2A-C) reveals that while the mGluR5-specific radioligand [ 11 C]ABP688 displays relatively similar binding across cortex and striatum with lower binding in other regions, [ 11 C]AZD9272 shows highest binding in striatum, thalamus and brainstem. These brain regions have a high density of the monoamine oxidase-B (MAO-B) enzyme (Saura et al., 1992; Tong et al., 2013) . Indeed, visual comparison of parametric images for [ 11 C]AZD9272 and, more recently, the images obtained at our laboratory using the MAO-B radioligand [ 11 C]L-deprenyl-D2 (Arakawa et al., 2017) shows strikingly similar distribution patterns in the human brain ( Fig. 2B and 2C) .
These observations may suggest that the signal obtained with [ 11 C]AZD9272 to some degree reflects binding to the MAO-B.
The objective of the present study was to test the hypothesis that the unique binding of fenobam and AZD9272 may represent specific binding to MAO-B. First, the correlation between the regional cerebral binding of [ 11 C]AZD9272 and [ 11 C]L-deprenyl-D2 was assessed based on evaluation of PET data previously acquired in human subjects. Second, the pharmacology of fenobam and AZD9272 binding sites was characterized by competition binding experiments carried out in vivo in PET studies of NHP, and in vitro, in tissue sections of selected human brain regions.
Material and methods

Compounds
[ 18 F]AZD9272 (molar activity, MA >10 GBq/µmol) was produced from its nitro precursor in a one-step fluorine-18 nucleophilic substitution reaction (Nag et al., 2018) . [ 11 C]L-deprenyl-D2 (MA >195 GBq/µmol) was produced as previously described elsewhere (Sturm et al., 2017) . [ 3 H]AZD9272 (MA, 0.51 GBq/µmol) was synthesized at AstraZeneca, Mölndal, Sweden as described in the supplementary material. Fenobam, AZD9272, and MTEP (Cosford et al., 2003; Fig. 1) were kindly provided by AstraZeneca and SL25.1188 (Hicks et al., 2015) was kindly provided by Dr. Kenneth Dahl, Harvard Medical School, Boston, MA, USA. Other compounds and chemicals were obtained from commercially available sources and were of analytical grade. 6
PET studies in human subjects
Data were obtained from five previous PET studies of human control subjects examined at the Karolinska Institutet PET centre using [ 11 C]AZD9272, [ 11 C]ABP688 or [ 11 C]L-deprenyl-D2 as radioligands ( Supplementary Table S1 ). Procedures for PET data acquisition have been described previously and parts of the data have been published Arakawa et al., 2017) . The studies were approved by the Research Ethics Committee in Stockholm, Sweden and the Radiation Safety Committee at Karolinska University Hospital, Stockholm, and were performed in accordance with the current amendment of the Declaration of Helsinki and International Conference on Harmonization/ Good Clinical Practice guidelines. Written informed consent was obtained from all participants.
Ten male subjects (aged 24-38 y), had been previously examined using [ 11 C]AZD9272, and 12 male subjects (aged 23-40 y) had been previously examined using [ 11 C]ABP688 as a radioligand. In addition to the subjects included in the two publications by Kågedal et al. (2012; n=6 for [ 11 C]AZD9272 and [ 11 C]ABP688, respectively), unpublished data acquired using the same PET methodology were in the present analysis included for 4 subjects examined using [ 11 C]AZD9272 and 6 subjects examined using [ 11 C]ABP688.
Finally, six subjects (age range, 21-62 years; four males, two females) who had been previously examined with [ 11 C]L-deprenyl-D2 were included (Arakawa et al., 2017) . Data for [ 11 C]ABP688 PET examinations (injected radioactivity 290-345 MBq), were acquired using the High Resolution Research Tomograph system (HRRT; Siemens Molecular Imaging, Knoxville, TN, USA) over 63 minutes, and data for [ 11 C]AZD9272 or [ 11 C]L-deprenyl-D2 (315-505 MBq) examinations were acquired using the ECAT Exact HR 47 system (Siemens/CTI, Knoxville, TN, USA) over 93 or 63 minutes, respectively.
For all subjects, individual T1-weighted brain magnetic resonance images (MRIs), acquired using a 1.5T system, were segmented into grey matter, white matter, and CSF as previously described (Arakawa et al., 2017) and co-registered with PET images. Regions of interest (ROIs) for analysis of radioligand binding were defined using the automated anatomical labelling template (Tzourio-Mazoyer et al., 2002) .
Regional time activity curves for [ 11 C]ABP688 and [ 11 C]AZD9272 were analysed using the Logan non-invasive approach (Logan et al., 1996) to estimate distribution volume ratios (DVRs) for ROIs relative to the cerebellum. For both tracers, the analysis was based on data from 63 minutes and the time of the linear phase (t*) was fixed at 15 min. Binding potential (BP ND ) was subsequently calculated based on regional estimates of DVR and volume of distribution (V T ) for the cerebellum and non-displaceable volume of distribution previously reported for [ 11 C]ABP688 (Kågedal et al., 2013) and [ 11 C]AZD9272 .
Procedures for analysis of [ 11 C]L-deprenyl-D2 PET data, to obtain the regional parameter K 1 /k 2 *k 3 (λk 3 ), have been previously described by Arakawa et al., (2017) . Parametric images were obtained for the purpose of visual inspection and comparison of the binding patterns for the different radioligands as described in the supplementary material.
Linear regression approaches were applied to disentangle the potential components of mGluR5 and MAO-B binding in the [ 11 C]AZD9272 images. Initially, simple linear regression and correlation analyses were performed between the regional binding of [ 11 C]AZD9272 and the binding of the mGluR5 and MAO-B specific radioligands, [ 11 C]ABP688 and [ 11 C]L-deprenyl-D2, respectively. Furthermore, in an attempt to gain a comprehensive understanding of the relative contributions of mGluR5 and MAO-B binding to the signal for [ 11 C]AZD9272, respectively, the relationship between the binding of [ 11 C]AZD9272 and both of these components was assessed in a combined multilinear regression analysis using regional BP ND for [ 11 C]AZD9272 as the dependent variable and regional BP ND for [ 11 C]ABP688 and λk 3 for [ 11 C]L-deprenyl-D2, respectively, as the independent variables. Specifically, the following model was fitted to the data:
(1).
PET studies in non-human primates
The study was approved by the Animal Ethics Committee of the Swedish Animal Welfare Agency (Dnr 145/08, 399/08 and 386/09) and was performed according to the "Guidelines for planning, conducting and documenting experimental research" (Dnr 4820/06-600) of the Karolinska Institutet and the "Guide for the Care and Use of Laboratory Animals" (Garber et al., 2011) . Four male NHPs (Macaca fascicularis), weighing 5.3-7.8 kg, were supplied by the Astrid Fagraeus Laboratory, Karolinska Institutet, Solna, Sweden.
In preparation for planned studies in human subjects an 18 F-labeled analogue of AZD9272 was developed. Importantly, in terms of biological and physicochemical properties the two molecules are identical. Moreover, a preliminary analysis indicates a similar pattern of radiometabolite formation for [ 18 F]AZD9272 and [ 11 C]AZD9272 in NHP plasma (Nag et al., 2018; Nag et al., manuscript) . PET measurements using [ 18 F]AZD9272 were carried out in Based on previous findings in NHP PET studies, the highest (1.0 mg/kg) dose of fenobam and MTEP was selected to reach approx. 80% occupancy of brain mGluR5 (DeLorenzo et al., 2011; Mathews et al., 2014) , whereas L-deprenyl (1.0 mg/kg) was expected to reach 70% occupancy of brain MAO-B (Nag et al., 2016) .
Test compounds were administered as a 10-minute intravenous infusion starting 15 minutes prior to the PET measurement for fenobam and MTEP and 45 minutes prior to the PET measurements for L-deprenyl based on previous investigations of these compounds (Nag et al., 2016; Varnäs et al., 2018) . The NHP was observed continuously during the PET experimental days. Body temperature was maintained by Bair Hugger heater -Model 505 (Arizant Healthcare Inc., MN) and monitored with an esophageal thermometer. Heart and respiration rates were continuously monitored during the experiment. The NHP head was immobilized in a head fixation system (Karlsson et al., 1993 Arterial blood was sampled as previously described (Finnema et al., 2014) using an automated blood sampling system during the first 3 minutes of each PET measurement.
Subsequently, arterial blood samples (0.7-3 mL) were manually drawn at 7, 15, 30, 60, 90
and 120 minutes after injection of [ 18 F]AZD9272 and at 5, 15, 30, 45, 60 and 90 minutes after injection of [ 11 C]L-deprenyl-D2. After centrifugation 0.2-1.5 mL plasma was pipetted and plasma radioactivity was measured in a well counter. In addition, samples were taken directly from the ABSS at 0.5, 1, 1.5, 2, 2.5 and 3 minutes for cross-calibration with the well counter and for determination of the plasma to blood ratio.
The fraction of plasma radioactivity corresponding to unchanged radioligand in plasma was determined from arterial plasma samples collected at 2, 7, 15, 30, 60, 90 and 120 minutes after injection of [ 18 F]AZD9272 and at 2, 5, 15, 30, 45, 60 and 90 minutes after injection of [ 11 C]L-deprenyl-D2 according to previously described procedures (Halldin et al., 1995) . The unbound fraction of radioligand in plasma was determined using ultrafiltration as reported in the literature (Moein et al., 2019) .
MRIs of the individual NHP brains had been previously obtained using a 3T General Electric
Discovery MR750 (GE, Milwakee, WI, USA) system. ROIs were manually delineated as previously described (Varnäs et al., 2018) on T1-weighted MRIs using an in-house image analysis software (Roland et al., 1994) . MRIs were coregistered to averaged PET images using SPM5 (Wellcome Department of Imaging Neuroscience, UK). Time-activity curves were generated by pooling ROIs for each paired anatomical region and applying the pooled ROIs to PET images using the affine transformation matrix acquired from coregistration of the MRI.
PET data were analyzed using the software PMOD v. 3.6. Regional estimates of the V T for [ 18 F]AZD9272 were obtained based on 75 minutes of data acquisition using the Logan linear graphical method (Logan et al., 1990 ) and t* fixed at 39 min. Occupancy at [ 18 F]AZD9272
binding sites was estimated based on regional V T values obtained at baseline and after drug administration according to a graphical method described in the literature (Cunningham et al., 2010 Brains were removed during autopsy and were handled in a manner similar to that described previously (Hall et al., 1998) . Tissue was obtained from 4 donors (2 males and 2 females; ages 32-82 y) with no known neurological or psychiatric diagnosis at the time of death.
Postmortem times were < 24 h for all cases. From visual inspection at autopsy and during sectioning, none of the brains exhibited damages or abnormalities.
Whole hemisphere tissue was cryosectioned using a heavy-duty cryomicrotome (Leica cryomacrocut CM3600, Leica, Nussloch, Germany). Cryosections with a slice thickness of 100 µm were transferred to gelatinized glass plates (10 × 22 cm), dried at room temperature and stored (-20°C) with dehydrating agents until use. In addition to the whole hemisphere sections, tissue sections from smaller blocks were used to detect binding in the brainstem, thalamus, and caudate nucleus. These frozen sections, with a thickness of 20 µm, were prepared from the tissue blocks in a cryomicrotome (Zeiss Microm HM560) and transferred to superfrost glass slides (SuperFrost®Plus, MenzelGläser, Germany). The slides were kept at -20°C until used.
Autoradiography -experimental procedure
Autoradiography studies were performed according to previously described procedures Varnäs et al., 2018) . Adjacent sections were incubated with [ 3 H]AZD9272 (3 nM) in the absence or presence of a saturating concentration (10 µM) of fenobam, the two mGluR5 NAMs MPEP and MTEP, or the MAO-B selective compounds L-deprenyl (Knoll and Magyar, 1972) and lazabemide (Henriot et al., 1994 ; Fig. 1 ). In addition, competition binding studies using [ 3 H]AZD9272 as a radioligand were undertaken at increasing concentrations (1 nM-10 µM) of MPEP or L-deprenyl, respectively.
Regional differences in inhibitor binding were further characterized in whole hemisphere sections (100 µm) at the level of thalamus and hippocampus. Since an 18 F-labeled analogue of AZD9272 having a higher molar radioactivity was developed during the course of the study (Nag et al., 2018) this radioligand was used for for detailed evaluation of these tissue samples. Adjacent sections were incubated with [ 18 F]AZD9272 (0.02 MBq/ml) in the absence or presence of a saturating 10 µM concentration of the five inhibitor substances listed above, or the MAO-B selective compound SL25.1188 (Hicks et al., 2015) .
Tissue sections were pre-incubated at room temperature for 30 min in the absence or presence of test compound in 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 7.4) containing 3 mM MgCl 2 and were subsequently incubated at room temperature for 60 min in the same incubation solutions containing radiolabeled AZD9272.
Sections were washed (2 × 5 min) in 50 mM HEPES/ 3 mM MgCl 2 buffer (4°C), rinsed in deionized water (4°C) and dried.
In autoradiography studies using [ 11 C]L-deprenyl-D2 as radioligand the sections were pre- were then washed and dried as previously described (Gulyás et al., 2011) .
Image analysis
Radioactivity was detected and quantified using a BAS-5000 phosphor imager (Fuji, Tokyo, Japan). Autoradiographic images (pixel size = 25 × 25 µm 2 ) were processed and quantified using the software Fiji (Schindelin et al., 2012) . Image pixel values were converted into photostimulated luminescence (PSL)/mm 2 units. For quantification of the binding of 
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Results
Regional radioligand binding in the human brain in vivo
Average parametric PET images for [ 11 C]ABP688, [ 11 C]L-deprenyl-D2 and [ 11 C]AZD9272, are shown in Fig. 2 . Visual inspection of parametric images for [ 11 C]AZD9272 showed conspicuous differences in binding patterns in comparison to that displayed by [ 11 C]ABP688, whereas the distribution for [ 11 C]AZD9272 and [ 11 C]L-deprenyl-D2 was similar in human brain ( Fig. 2A-C) . Radioligand binding patterns were compared on the basis of regional estimates for availability of binding sites (BP ND ) for [ 11 C]AZD9272 and [ 11 C]ABP688 as well as λk 3 for [ 11 C]L-deprenyl-D2. All regional parameter estimates are presented in Supplementary Table S2 .
The rank order for the regional BP ND values obtained for [ 11 C]AZD9272 (striatum > amygdala > thalamus > hippocampus > pons > isocortex > cerebellum) differed from that for [ 11 C]ABP688 (isocortex ~ striatum > hippocampus > amygdala > thalamus > pons > cerebellum), but was consistent with the binding pattern displayed by [ 11 C]L-deprenyl-D2.
Regional BP ND values for [ 11 C]AZD9272 did not correlate at a statistically significant level, with corresponding values for [ 11 C]ABP688 (Pearson R 2 = 0.00; P = 0.979; Fig. 3A ), but were strongly correlated with regional estimates of λk 3 for [ 11 C]L-deprenyl-D2 binding (Pearson R 2 = 0.95; P = 2×10 -16 ; Fig. 3B ).
Correspondingly, according to the two linear regressions, the regional binding of [ 11 C]Ldeprenyl-D2 was more suitable than that of [ 11 C]ABP688 at predicting the binding of [ 11 C]AZD9272 (Akaike information criterion, AIC, of -8.0 vs. 66.5, respectively; Fig. 3A and   3B ). It should be noted that the residuals of the linear regression between [ 11 C]AZD9272 and [ 11 C]L-deprenyl-D2 binding parameters showed a moderate and significant correlation with the binding of [ 11 C]ABP688 (Pearson R 2 = 0.62, P = 3×10 -6 ; Supplementary Figure S1 ).
An attempt was made using a multiple linear regression approach to disentangle the components of MAO-B and mGluR5 binding in the [ 11 C]AZD9272 images. Parametric images predicting BP ND for [ 11 C]AZD9272 based on the multilinear model and [ 11 C]ABP688
and [ 11 C]L-deprenyl-D2 data as predictors were generated (Fig. 2D) . The parametric images displayed high similarity with the corresponding average parametric images for [ 11 C]AZD9272 (Fig. 2C) .
Consequently, the multilinear regression indicated that predictions of [ 11 C]AZD9272 binding using both mGluR5-specific ([ 11 C]ABP688) and MAO-B-specific ([ 11 C]L-deprenyl-D2) components had the highest degree of correlation (Pearson R 2 = 0.98, P = 1×10 -20 ) and best agreement (AIC=-29.5) with the observed BP ND values (Fig. 3C ). According to the multilinear model, roughly 15% (5-20%) of regional BP ND of [ 11 C]AZD9272 is due to mGluR5-specific binding with higher contributions in cortical areas and lower in striatum, thalamus or pons ( Fig. 3C and Fig. S2 ). Furthermore, visual inspection of the parametric image predicting [ 11 C]AZD9272 binding using the multilinear model on the voxel level ( Fig.   2D ) showed best overall similarity to the observed mean binding image (Fig. 2C ), in particular with regard to the higher cortical binding levels when compared to the pattern seen in the [ 11 C]L-deprenyl-D2 image (Fig. 2B ).
Pharmacological characterization of fenobam and AZD9272 binding
In vivo characterization in NHP brain
Altogether eight PET measurements were conducted with [ 18 F]AZD9272 and four with Fig. 4; Fig. S3 ). In the [ 11 C]L-deprenyl-D2 PET measurements in two NHPs, administration of 1.0 mg/kg fenobam inhibited 20 and 40% of the specific binding in thalamus and 30 and 34% of the specific binding in ventral midbrain (Table S3 ).
In vitro characterization in human brain tissue
In cryosections of the human thalamus and brainstem fenobam (10 µM) inhibited 97-99% of incubating brain sections at increasing concentrations of inhibitor (1 nM-10 µM; Fig. 6 ), the binding of [ 3 H]AZD9272 was more potently inhibited by L-deprenyl than by MPEP in thalamus (IC 50 , 3.7 nM vs. 1.8 µM) and substantia nigra (IC 50 , 3.7 nM vs. 4.6 µM).
Regional differences in inhibitor occupancy were assessed using [ 18 F]AZD9272 at a high molar radioactivity in whole hemisphere sections of the human brain. Fenobam inhibited binding to the same extent in all brain regions, whereas no evident inhibitory effect on radioligand binding was observed in sections co-incubated with MTEP (results not shown).
MPEP potently inhibited binding in the cortex and CA1 region of the hippocampus, whereas parts of the signal remained in the thalamus, CA3 of the hippocampus, dentate gyrus and the ependyma of the ventricle. L-deprenyl, lazabemide, or SL25.1188 inhibited [ 18 F]AZD9272 binding in the CA3/dentate gyrus, thalamus and ependyma of the ventricle, but displayed low occupancy in the CA1 region and cortex (Fig. S4) .
The binding of [ 11 C]L-deprenyl-D2 in human thalamus and brainstem was potently inhibited by fenobam or AZD9272 (75-80% inhibition at 100 nM and 99% inhibition at 10 µM). The binding was only partially inhibited by MPEP (16-19% at 100 nM and 93% at 10 µM) or MTEP (14-15% at 100 nM and 66-67% at 10 µM; Fig. 7 ).
Discussion
The mGluR5 NAMs fenobam and AZD9272 have been reported to have a propensity to induce psychotic symptoms in humans and have previously been found to recognize a shared, non-mGluR5-related, site in primate brain (Varnäs et al., 2018) . Based on the high density of AZD9272 binding sites in brain regions expressing MAO-B, this enzyme was considered as a potential explanation for the non-target binding of fenobam and AZD9272. Major observations of the present study were that the distribution pattern for [ 11 C]AZD9272 is strongly correlated with the binding of the MAO-B radioligand [ 11 C]L-deprenyl-D2 in the human brain, that the binding of radiolabeled AZD9272 can be inhibited by fenobam, or by MAO-B specific compounds, and finally, that the binding of [ 11 C]L-deprenyl-D2 can be inhibited by AZD9272 or fenobam. Taken together, these findings are consistent with the hypothesis that fenobam and AZD9272 bind to the MAO-B enzyme in the NHP and human brain.
Based on PET data acquired for human subjects the regional binding of [ 11 C]AZD9272 was strongly correlated with the binding to MAO-B with a small contribution of mGluR5 binding recognition sites in rodent brain indicating selective binding to mGluR5 . Importantly, the density of MAO-B has been shown to be lower in rat than in human brain, where the MAO-B is more abundantly expressed in comparison to neuroreceptors, such as mGluR5 (Saura et al., 1992; Patel et al., 2007; Tong et al., 2013) , thus supporting the view that species differences in the relative availability of mGluR5 and MAO-B may account for these discrepancies in selectivity.
The MAO-B compound L-deprenyl inhibited the binding of radiolabeled AZD9272 in vivo in the NHP brain (87% occupancy at 1.0 mg/kg) and in vitro in human brain tissue (IC 50 , 3.7 nM). To further assess whether this effect may be due to competition at MAO-B the inhibition of radiolabeled AZD9272 binding was also examined by autoradiography in presence of the structurally distinct MAO-B ligands lazabemide or SL25.1188. The regional inhibition of radioligand binding induced by these compounds was consistent with that observed for L-deprenyl thus corroborating the hypothesis that L-deprenyl inhibits AZD9272
binding to the MAO-B.
The binding of radiolabeled AZD9272 in vivo was potently inhibited by fenobam (84% occupancy at 1.0 mg/kg), but was less sensitive to MTEP (<5% occupancy at 1.0 mg/kg).
MTEP and fenobam, administered at the 1 mg/kg dose level, have previously been reported to occupy 70-90% of specific binding for [ 11 C]ABP688 at the mGluR5 in PET studies of the baboon brain (DeLorenzo et al., 2011; Mathews et al., 2014) . The negligible impact of the selective mGluR5 ligand MTEP on [ 18 F]AZD9272 binding is consistent with our previous observations with 11 C-labeled AZD9272 (Varnäs et al., 2018) , but in stark contrast to the major impact on [ 11 C]ABP688 binding (90% occupancy at 1 mg/kg; DeLorenzo et al., 2011).
The occupancy induced by fenobam at AZD9272 binding sites (ID 50 =0.21 mg/kg) is of the same magnitude as that previously reported for inhibition of the binding of [ 11 C]ABP688
(ID 50 = 0.3-1.1 mg/kg; Mathews et al., 2014) . Taken together, these observations may support that the affinity of fenobam for mGluR5 and MAO-B is of the same order in vivo.
The binding of [ 11 C]L-deprenyl-D2 in vitro was markedly inhibited by AZD9272 and fenobam, but was less sensitive to MPEP and MTEP (Fig. 7) . Observations that the binding of AZD9272 and L-deprenyl is mutually displaceable, and the consistent rank order of compound potency (fenobam > MPEP > MTEP) for inhibiting the respective radioligand binding further support that AZD9272, L-deprenyl and fenobam recognize a common site.
As part of initial drug development, AZD9272 has in routine pharmacological characterization been found to be selective for mGluR5 against 134 receptors, ion channels, transporters and enzymes . However, this in vitro screening did not include MAO-B as a target. With regard to fenobam, our findings are in some contrast to the low affinity previously reported for the rat peripheral MAO-B (K i >20 µM; Keck et al., 2014) .
Species differences in fenobam binding to rat vs. primate MAO-B are not supported by our observation that fenobam inhibited the binding of [ 11 C]L-deprenyl-D2 also in rat brain in vitro (98% inhibition at 10 µM; unpublished data). However, such discrepancies could result from the use of different radioligands, assay conditions, or be due to possible differences in ligand recognition properties of central vs. peripheral MAO-B. (Fowler et al., 1980) , suggesting that the proportional binding to MAO-B may be lower for the subjects examined using [ 11 C]AZD9272 than for the subjects examined using [ 11 C]L-deprenyl-D2 as a radioligand. However, these differences are not expected to confound the correlation of radioligand binding parameters, since age-related increases in MAO-B availability have been reported to be similar across brain regions (Fowler et al., 1980; Fowler et al., 1997) .
PET images for [ 11 C]ABP688 were acquired using a different system at higher anatomical resolution (HRRT, 2 mm at full width at half maximum, FWHM; Varrone et al., 2009 ) than images for [ 11 C]AZD9272 and [ 11 C]L-deprenyl-D2 (ECAT HR; 3.6-4.0 mm at FWHM; Wienhard et al., 1994) . Nevertheless, differences in PET system resolution are unlikely to explain the higher signal for [ 11 C]AZD9272 than for [ 11 C]ABP688, since a lower resolution PET system would be expected to underestimate binding in the small brain structures labeled by AZD9272 (Schain et al., 2012) . Moreover, discrepancies in regional binding for [ 11 C]AZD9272 and [ 11 C]ABP688 in the brain of NHPs have been previously found in PET studies carried out using the same PET system (Varnäs et al., 2018) , supporting that differences in PET system resolution cannot account for the observed variation in binding density or radioligand distribution patterns.
Psychosis-like symptoms have been reported in clinical studies of fenobam (Friedmann et al., 1980; Pecknold et al., 1982) and AZD9272 (Ståhle et al., 2012) . The present observation of a shared binding site of fenobam, AZD9272 and MAO-B inhibitors raises the possibility that such psychotic symptoms are partly mediated through mechanisms involving MAO-B. There is early evidence that non-selective MAO inhibitors may precipitate psychosis (reviewed by Price and Hopkinson, 1968) . For instance, hallucinations and paranoid delusions have been reported after use of the MAO inhibitor pargyline for treatment of hypertension (Sutnick et al., 1964) and the MAO inhibitors isoniazid and iproniazid for treatment of tuberculosis (Pleasure, 1954) . Though selective MAO-B inhibitors have been less frequently reported to induce psychotic symptoms, treatment with L-deprenyl has been found to be weakly correlated with hallucinations in Parkinson's disease (Williams and Lees, 2005) . These reports in the literature of similar symptoms with MAO compounds may suggest involvement of MAO-B-related mechanisms in fenobam-and AZD9272-associated adverse events.
However, it cannot be excluded that mechanisms involving both MAO-B and mGluR5 may contribute to the psychosis-like effects observed with these compounds. A more detailed understanding of MAO-B and mGluR5 in relation to psychotic symptoms may serve to generate novel pharmacological models for psychosis.
Conclusions
Converging evidence based on the localization and pharmacology of AZD9272 binding sites supports the hypothesis that fenobam and AZD9272 bind predominantly to the MAO-B enzyme in primate brain. Based on previous observations of psychosis-like adverse events in human subjects receiving fenobam or AZD9272 it can be suggested that MAO-B-related mechanisms may be of relevance for these effects. , AZD9272 , fenobam (Porter et al., 2005) , lazabemide (Henriot et al., 1994) , L-deprenyl (Knoll and Magyar, 1972) , MPEP (Gasparini et al., 1999) , MTEP (Cosford et al., 2003) and SL25.1188 (Hicks et al., 2015) . Figure 3C also indicates the predicted mGluR5-specific and MAO-B-specific components of regional Binding to MAO-B may possibly explain some adverse events of these compounds.
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